Mostrar el registro sencillo del ítem
Diagnostic effectiveness of [123I] Ioflupane single photon emission computed tomography (SPECT) in multiple system atrophy
dc.contributor.author | Villena-Salinas, Javier | |
dc.contributor.author | Ortega-Lozano, Simeón José | |
dc.contributor.author | Amrani-Raissouni, Tomader | |
dc.contributor.author | Agüera Morales, Eduardo | |
dc.contributor.author | Caballero-Villarraso, Javier | |
dc.date.accessioned | 2023-06-01T12:07:04Z | |
dc.date.available | 2023-06-01T12:07:04Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2077-0383 | |
dc.identifier.uri | http://hdl.handle.net/10396/25449 | |
dc.description.abstract | Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder that has no curative treatment. Diagnosis is based on a set of criteria established by Gilman (1998 and 2008) and recently updated by Wenning (2022). We aim to determine the effectiveness of [123I]Ioflupane SPECT in MSA, especially at the initial clinical suspicion. Methods: A cross-sectional study of patients at the initial clinical suspicion of MSA, referred for [123I]Ioflupane SPECT. Results: Overall, 139 patients (68 men, 71 women) were included, 104 being MSA-probable and 35 MSA-possible. MRI was normal in 89.2%, while SPECT was positive in 78.45%. SPECT showed high sensitivity (82.46%) and positive predictive value (86.24), reaching maximum sensitivity in MSA-P (97.26%). Significant differences were found when relating both SPECT assessments in the healthy–sick and inconclusive–sick groups. We also found an association when relating SPECT to the subtype (MSA-C or MSA-P), as well as to the presence of parkinsonian symptoms. Lateralization of striatal involvement was detected (left side). Conclusions: [123I]Ioflupane SPECT is a useful and reliable tool for diagnosing MSA, with good effectiveness and accuracy. Qualitative assessment shows a clear superiority when distinguishing between the healthy–sick categories, as well as between the parkinsonian (MSA-P) and cerebellar (MSA-C) subtypes at initial clinical suspicion. | en |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/ | es_ES |
dc.source | J. Clin. Med., 12(10), 3478 (2023) | es_ES |
dc.subject | Applications of Biomedical Technology | en |
dc.subject | Molecular Biological Approach | en |
dc.subject | Brain Diseases | en |
dc.title | Diagnostic effectiveness of [123I] Ioflupane single photon emission computed tomography (SPECT) in multiple system atrophy | en |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/jcm12103478 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |